vs

Side-by-side financial comparison of ALPHA & OMEGA SEMICONDUCTOR Ltd (AOSL) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $162.3M, roughly 2.0× ALPHA & OMEGA SEMICONDUCTOR Ltd). ALPHA & OMEGA SEMICONDUCTOR Ltd runs the higher net margin — -8.2% vs -18.2%, a 10.1% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -6.3%). ALPHA & OMEGA SEMICONDUCTOR Ltd produced more free cash flow last quarter ($-23.1M vs $-133.8M).

Alpha & Omega Semiconductor Ltd designs, manufactures and markets a broad portfolio of power semiconductors, including power MOSFETs, IGBTs, analog ICs and power management modules. Its products are applied across consumer electronics, industrial equipment, automotive systems, telecom and computing segments, with sales networks covering major global markets.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

AOSL vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
2.0× larger
MDGL
$321.1M
$162.3M
AOSL
Growing faster (revenue YoY)
MDGL
MDGL
+217.1% gap
MDGL
210.8%
-6.3%
AOSL
Higher net margin
AOSL
AOSL
10.1% more per $
AOSL
-8.2%
-18.2%
MDGL
More free cash flow
AOSL
AOSL
$110.8M more FCF
AOSL
$-23.1M
$-133.8M
MDGL

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AOSL
AOSL
MDGL
MDGL
Revenue
$162.3M
$321.1M
Net Profit
$-13.3M
$-58.6M
Gross Margin
21.5%
Operating Margin
-8.4%
-18.6%
Net Margin
-8.2%
-18.2%
Revenue YoY
-6.3%
210.8%
Net Profit YoY
-101.0%
1.4%
EPS (diluted)
$-0.45
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOSL
AOSL
MDGL
MDGL
Q4 25
$162.3M
$321.1M
Q3 25
$182.5M
$287.3M
Q2 25
$176.5M
$212.8M
Q1 25
$164.6M
$137.3M
Q4 24
$173.2M
$103.3M
Q3 24
$181.9M
$62.2M
Q2 24
$161.3M
Q1 24
$150.1M
$0
Net Profit
AOSL
AOSL
MDGL
MDGL
Q4 25
$-13.3M
$-58.6M
Q3 25
$-2.1M
$-114.2M
Q2 25
$-77.1M
$-42.3M
Q1 25
$-10.8M
$-73.2M
Q4 24
$-6.6M
$-59.4M
Q3 24
$-2.5M
$-107.0M
Q2 24
$-2.7M
Q1 24
$-11.2M
$-147.5M
Gross Margin
AOSL
AOSL
MDGL
MDGL
Q4 25
21.5%
Q3 25
23.5%
Q2 25
23.4%
Q1 25
21.4%
96.7%
Q4 24
23.1%
Q3 24
24.5%
Q2 24
25.7%
Q1 24
23.7%
Operating Margin
AOSL
AOSL
MDGL
MDGL
Q4 25
-8.4%
-18.6%
Q3 25
-2.5%
-39.7%
Q2 25
-6.6%
-22.2%
Q1 25
-6.5%
-57.8%
Q4 24
-3.4%
-64.8%
Q3 24
-0.1%
-187.1%
Q2 24
-0.9%
Q1 24
-7.0%
Net Margin
AOSL
AOSL
MDGL
MDGL
Q4 25
-8.2%
-18.2%
Q3 25
-1.2%
-39.8%
Q2 25
-43.7%
-19.9%
Q1 25
-6.6%
-53.4%
Q4 24
-3.8%
-57.5%
Q3 24
-1.4%
-172.0%
Q2 24
-1.7%
Q1 24
-7.5%
EPS (diluted)
AOSL
AOSL
MDGL
MDGL
Q4 25
$-0.45
$-2.55
Q3 25
$-0.07
$-5.08
Q2 25
$-2.61
$-1.90
Q1 25
$-0.37
$-3.32
Q4 24
$-0.23
$-2.50
Q3 24
$-0.09
$-4.92
Q2 24
$-0.09
Q1 24
$-0.39
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOSL
AOSL
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$196.3M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$818.8M
$602.7M
Total Assets
$1.0B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOSL
AOSL
MDGL
MDGL
Q4 25
$196.3M
$198.7M
Q3 25
$223.5M
$295.7M
Q2 25
$153.1M
$186.2M
Q1 25
$169.4M
$183.6M
Q4 24
$182.6M
$100.0M
Q3 24
$176.0M
$232.7M
Q2 24
$175.1M
Q1 24
$174.4M
$622.5M
Total Debt
AOSL
AOSL
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$14.9M
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
$26.7M
Q1 24
$116.1M
Stockholders' Equity
AOSL
AOSL
MDGL
MDGL
Q4 25
$818.8M
$602.7M
Q3 25
$834.1M
$625.7M
Q2 25
$822.3M
$696.0M
Q1 25
$886.3M
$710.6M
Q4 24
$902.6M
$754.4M
Q3 24
$895.3M
$777.2M
Q2 24
$891.6M
Q1 24
$888.9M
$850.8M
Total Assets
AOSL
AOSL
MDGL
MDGL
Q4 25
$1.0B
$1.3B
Q3 25
$1.0B
$1.4B
Q2 25
$1.0B
$1.0B
Q1 25
$1.1B
$996.6M
Q4 24
$1.1B
$1.0B
Q3 24
$1.1B
$1.1B
Q2 24
$1.1B
Q1 24
$1.2B
$1.1B
Debt / Equity
AOSL
AOSL
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.02×
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
0.03×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOSL
AOSL
MDGL
MDGL
Operating Cash FlowLast quarter
$-8.1M
$-133.5M
Free Cash FlowOCF − Capex
$-23.1M
$-133.8M
FCF MarginFCF / Revenue
-14.2%
-41.7%
Capex IntensityCapex / Revenue
9.2%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-40.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOSL
AOSL
MDGL
MDGL
Q4 25
$-8.1M
$-133.5M
Q3 25
$10.2M
$79.8M
Q2 25
$-2.8M
$-47.1M
Q1 25
$7.4M
$-88.9M
Q4 24
$14.1M
$-104.5M
Q3 24
$11.0M
$-67.0M
Q2 24
$7.1M
Q1 24
$28.2M
$-149.2M
Free Cash Flow
AOSL
AOSL
MDGL
MDGL
Q4 25
$-23.1M
$-133.8M
Q3 25
$420.0K
$79.0M
Q2 25
$-17.2M
Q1 25
$-1.1M
Q4 24
$6.6M
$-104.7M
Q3 24
$4.1M
$-67.8M
Q2 24
$-210.0K
Q1 24
$20.5M
$-149.5M
FCF Margin
AOSL
AOSL
MDGL
MDGL
Q4 25
-14.2%
-41.7%
Q3 25
0.2%
27.5%
Q2 25
-9.7%
Q1 25
-0.6%
Q4 24
3.8%
-101.3%
Q3 24
2.3%
-109.0%
Q2 24
-0.1%
Q1 24
13.7%
Capex Intensity
AOSL
AOSL
MDGL
MDGL
Q4 25
9.2%
0.1%
Q3 25
5.4%
0.3%
Q2 25
8.1%
0.0%
Q1 25
5.1%
0.0%
Q4 24
4.3%
0.2%
Q3 24
3.8%
1.3%
Q2 24
4.5%
Q1 24
5.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOSL
AOSL

Power Discrete$101.0M62%
Power Ic$58.8M36%
Packaging And Testing Services$2.5M2%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons